We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
Read MoreHide Full Article
Smith & Nephew plc (SNN - Free Report) closed its acquisition of Switzerland-based Atracsys Sàrl, the provider of optical tracking technology used in computer-assisted surgery. The deal, initiated in June 2019, is in line with the company’s strategy to invest in cutting-edge technologies, which will help accelerate its presence in the multi-asset digital surgery and robotic ecosystem space.
However, the financial terms of the deal were kept under wraps.
Atracsys Business at a Glance
Atracsys’ portfolio includes open platform optical navigation and robotic tracking components with applications in orthopaedics, neurosurgery, spine and dental.
With this purchase, Atracsys’ fusionTrack 500 optical tracking camera will be a core enabling technology for Smith & Nephew’s next-generation robotics platform that will be commercially released in 2020.
As compared to the existing tracking technology, the fusionTrack 500 system offers better measurement of speed and latency performance that supports reduced procedure time as well as increases accuracy resulting in finer precision surgical tasks like the bone cuts.
Smith & Nephew's M&As Continue
Smith & Nephew is fortifying its footprint through its inorganic growth path. Last month, the company completed its buyout of Brainlab orthopaedic joint reconstruction business. This business provides digital workflow tools starting from pre-operative planning to intraoperative navigation to post-operative evaluation and sharing.
In April, it concluded the acquisitions of regenerative medicine products maker Osiris Therapeutics and Leaf Healthcare, the developer of the unique Leaf Patient Monitoring System.
Earlier, in January, the company culminated the consolidation of CeterixOrthopadics, the developer of NovoStitch Pro, a device for meniscal repair.
Price Performance
In the past three months, shares of the company have outperformed its industry. The stock has rallied 11.7% compared with the industry’s 4.7% rise.
Zacks Rank & Other Key Picks
Smith & Nephew currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are Haemonetics Corporation (HAE - Free Report) , DENTSPLY SIRONA (XRAY - Free Report) and Penumbra (PEN - Free Report) . While Haemonetics sports a Zacks Rank #1 (Strong Buy), the other two hold a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has a long-term earnings growth rate of 13.5%.
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
Smith & Nephew plc (SNN - Free Report) closed its acquisition of Switzerland-based Atracsys Sàrl, the provider of optical tracking technology used in computer-assisted surgery. The deal, initiated in June 2019, is in line with the company’s strategy to invest in cutting-edge technologies, which will help accelerate its presence in the multi-asset digital surgery and robotic ecosystem space.
However, the financial terms of the deal were kept under wraps.
Atracsys Business at a Glance
Atracsys’ portfolio includes open platform optical navigation and robotic tracking components with applications in orthopaedics, neurosurgery, spine and dental.
With this purchase, Atracsys’ fusionTrack 500 optical tracking camera will be a core enabling technology for Smith & Nephew’s next-generation robotics platform that will be commercially released in 2020.
As compared to the existing tracking technology, the fusionTrack 500 system offers better measurement of speed and latency performance that supports reduced procedure time as well as increases accuracy resulting in finer precision surgical tasks like the bone cuts.
Smith & Nephew's M&As Continue
Smith & Nephew is fortifying its footprint through its inorganic growth path. Last month, the company completed its buyout of Brainlab orthopaedic joint reconstruction business. This business provides digital workflow tools starting from pre-operative planning to intraoperative navigation to post-operative evaluation and sharing.
In April, it concluded the acquisitions of regenerative medicine products maker Osiris Therapeutics and Leaf Healthcare, the developer of the unique Leaf Patient Monitoring System.
Earlier, in January, the company culminated the consolidation of CeterixOrthopadics, the developer of NovoStitch Pro, a device for meniscal repair.
Price Performance
In the past three months, shares of the company have outperformed its industry. The stock has rallied 11.7% compared with the industry’s 4.7% rise.
Zacks Rank & Other Key Picks
Smith & Nephew currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are Haemonetics Corporation (HAE - Free Report) , DENTSPLY SIRONA (XRAY - Free Report) and Penumbra (PEN - Free Report) . While Haemonetics sports a Zacks Rank #1 (Strong Buy), the other two hold a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has a long-term earnings growth rate of 13.5%.
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>